MX2017013396A - Clonidina y/o derivados de clonidina para uso en la prevencion y/o tratamiento de efectos secundarios adversos de quimioterapia. - Google Patents

Clonidina y/o derivados de clonidina para uso en la prevencion y/o tratamiento de efectos secundarios adversos de quimioterapia.

Info

Publication number
MX2017013396A
MX2017013396A MX2017013396A MX2017013396A MX2017013396A MX 2017013396 A MX2017013396 A MX 2017013396A MX 2017013396 A MX2017013396 A MX 2017013396A MX 2017013396 A MX2017013396 A MX 2017013396A MX 2017013396 A MX2017013396 A MX 2017013396A
Authority
MX
Mexico
Prior art keywords
clonidine
treatment
side effects
adverse side
chemotherapy
Prior art date
Application number
MX2017013396A
Other languages
English (en)
Inventor
Vasseur-Demarcy Bérangère
Attali Pierre
Original Assignee
Monopar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc filed Critical Monopar Therapeutics Inc
Publication of MX2017013396A publication Critical patent/MX2017013396A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C07C25/08—Dichloro-benzenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de clonidina y/o clonidina específicos para su uso en la prevención y/o tratamiento de efectos secundarios adversos de la quimioterapia del agente alquilante, que resultan de la inflamación mucosal. También se refiere al uso de esta clonidina y/o derivado de clonidina para la fabricación de una composición farmacéutica destinada a prevenir y/o aliviar los efectos secundarios adversos de la quimioterapia del agente alquilante distintos de los que resultan de la inflamación mucosal. Esta invención se refiere además a un kit que comprende: (a) un derivado de clonidina y/o clonidina, y (b) al menos un agente quimioterapéutico alquilante, como una preparación combinada para uso simultáneo, separado o secuencial en el tratamiento del cáncer.
MX2017013396A 2015-04-17 2015-04-17 Clonidina y/o derivados de clonidina para uso en la prevencion y/o tratamiento de efectos secundarios adversos de quimioterapia. MX2017013396A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/058419 WO2016165775A1 (en) 2015-04-17 2015-04-17 Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy

Publications (1)

Publication Number Publication Date
MX2017013396A true MX2017013396A (es) 2018-06-13

Family

ID=52824258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013396A MX2017013396A (es) 2015-04-17 2015-04-17 Clonidina y/o derivados de clonidina para uso en la prevencion y/o tratamiento de efectos secundarios adversos de quimioterapia.

Country Status (13)

Country Link
US (1) US10675271B2 (es)
EP (1) EP3283072A1 (es)
JP (1) JP6629344B2 (es)
KR (1) KR102375047B1 (es)
CN (1) CN108307631B (es)
AU (1) AU2015391685B2 (es)
BR (1) BR112017022321B1 (es)
CA (1) CA2982460C (es)
IL (1) IL255001B (es)
MX (1) MX2017013396A (es)
NZ (1) NZ736241A (es)
WO (1) WO2016165775A1 (es)
ZA (1) ZA201706884B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5417070A (en) 1977-07-07 1979-02-08 Sony Tektronix Corp Waveform monitor
DE3168754D1 (en) * 1980-07-09 1985-03-21 Beecham Group Plc Clonidine derivatives useful in the treatment of diarrhoea
FR2665357B1 (fr) 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
US6610720B2 (en) * 2000-08-24 2003-08-26 Merck Frosst Canada & Co. Method for treating or preventing emesis
CN1329887A (zh) * 2001-06-29 2002-01-09 徐州颐华医药科技有限公司 可乐定作为镇痛剂的应用
US20060194878A1 (en) * 2002-10-07 2006-08-31 Lopaschuk Gary D Methods of cardioprotection using dichloroacetate in combination with an inotrope
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXPA06002716A (es) 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
FR2889417B1 (fr) 2005-08-05 2008-02-08 Roquette Freres Proteines de pois texturee
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
EP1972332A1 (en) 2007-03-23 2008-09-24 BioAlliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
EP2165706A1 (en) * 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
EP2368549A1 (en) 2010-03-25 2011-09-28 BioAlliance Pharma Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
US10350695B2 (en) 2010-06-14 2019-07-16 Esab Ab Method of automatically setting a welding parameter for MIG/MAG welding and a controller for performing the method
RU2578412C1 (ru) * 2014-12-02 2016-03-27 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтическая композиция для лечения астении и/или синдрома хронической усталости

Also Published As

Publication number Publication date
CA2982460C (en) 2023-05-23
JP2018511641A (ja) 2018-04-26
US10675271B2 (en) 2020-06-09
EP3283072A1 (en) 2018-02-21
KR102375047B1 (ko) 2022-03-15
US20180098966A1 (en) 2018-04-12
CN108307631B (zh) 2021-11-23
AU2015391685A1 (en) 2017-11-02
CA2982460A1 (en) 2016-10-20
WO2016165775A1 (en) 2016-10-20
CN108307631A (zh) 2018-07-20
KR20170137190A (ko) 2017-12-12
BR112017022321B1 (pt) 2023-03-14
IL255001A0 (en) 2017-12-31
IL255001B (en) 2020-10-29
JP6629344B2 (ja) 2020-01-15
BR112017022321A2 (pt) 2018-07-03
AU2015391685B2 (en) 2021-07-01
ZA201706884B (en) 2021-02-24
NZ736241A (en) 2022-11-25

Similar Documents

Publication Publication Date Title
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2023010042A (es) Polinucleotidos moduladores.
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
PH12016501702B1 (en) Pyrazole amide derivative
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
MX2019005349A (es) Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
EP3733212A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER METASTASIS IN THE LUNG WITH CHI3L1 INHIBITOR AS THE ACTIVE SUBSTANCE
MX2017009608A (es) Compuestos anticancerigenos.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2017013396A (es) Clonidina y/o derivados de clonidina para uso en la prevencion y/o tratamiento de efectos secundarios adversos de quimioterapia.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
WO2016187620A3 (en) Anti-cancer compounds
MX2016013108A (es) Nueva composicion para el tratamiento de la tricomoniasis.
GB2546703A (en) Compounds